Number of patients
|
220
|
32
|
137
|
51
|
ASAS20 responders at three months
|
68%
|
80%
|
66%
|
65%
|
(number of patients)
|
(145 of 214)
|
(24 of 30)
|
(88 of 133)
|
(33 of 51)
|
ASAS20 responders at six months
|
63%
|
71%
|
66%
|
51%
|
(number of patients)
|
(132 of 209)
|
(22 of 31)
|
(86 of 131)
|
(24 of 47)
|
ASAS40 responders at three months
|
49%
|
63%
|
47%
|
45%
|
(number of patients)
|
(104 of 214)
|
(19 of 30)
|
(62 of 133)
|
(23 of 51)
|
ASAS40 responders at six months
|
46%
|
52%
|
48%
|
38%
|
(number of patients)
|
(97 of 209)
|
(16 of 31)
|
(63 of 131)
|
(18 of 47)
|
BASDAI50 responders at three months
|
49%
|
60%
|
46%
|
51%
|
(number of patients)
|
(105 of 214)
|
(18 of 30)
|
(61 of 133)
|
(26 of 51)
|
BASDAI50 responders at six months
|
50%
|
48%
|
51%
|
47%
|
(number of patients)
|
(104 of 209)
|
(15 of 31)
|
(67 of 131)
|
(22 of 47)
|
One-year drug survival
|
71%
|
76%
|
72%
|
65%
|
(number of patients)
|
(136 of 192)
|
(22 of 29)
|
(88 of 123)
|
(26 of 40)
|
Two-year drug survival
|
66%
|
70%
|
69%
|
48%
|
(number of patients)
|
(97 of 148)
|
(19 of 27)
|
(66 of 96)
|
(12 of 25)
|